View

The Study

Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men

In simple terms

This study looked at men who took testosterone medicine and those who didn’t, and saw that the ones who took it didn’t get more prostate cancer or die more from heart problems. But because it wasn’t a fair test where people were randomly assigned, we can’t say the medicine caused the difference — it might just be that healthier men were more likely to get the medicine.

53%

Analysis score

53/ 72

Maximum 72 for a cohort study.

Where the score came from

Reporting0
Methodology56
Publication100
Statistical54
Study type (basis of the score)
Cohort Study
Level 2b - Individual cohort study
What’s the bottom line?

This study looked at older men who took testosterone medicine and compared them to men who didn't. It tracked them for 18 years to see if they got more cancer or died more from heart issues.

Where does this study sit?

Systematic Reviews & Meta-analyses

Max 100

Randomized Trials

Max 90

Cohort Studies

Max 72

Case-Control

Max 58

Cross-Sectional

Max 44

Case Reports & Series

Max 30

Expert Opinion

Max 5
StrongerWeaker
Cohort Studies
Level 2
53

53 / 100

Quality score

Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.

Cannot establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1The lower death rates are meaningful — especially the nearly half reduction in prostate cancer deaths — but the heart disease and overall death benefits are small and not strongly certain.
  2. 22,919 men took testosterone; 285 got prostate cancer.
  3. 3Those on testosterone were 48% less likely to die from prostate cancer, 13% less likely to die from heart disease, and 7% less likely to die from any cause.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Acta Oncologica

Year

2023

Authors

A. Siltari, T. Murtola, Josefina Kausz, K. Talala, K. Taari, T. Tammela, Anssi Auvinen

Open Access
8 citations
Analysis v3
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.